Telix Pharmaceuticals (TLX) said Tuesday it received "encouraging" preliminary results from an eight-patient phase 2 study of TLX101 in combination with radiation therapy as a potential treatment for recurrent high-grade glioma, a form of brain cancer.
The company said the study showed a median overall survival of 12.4 months for patients treated with the TLX101-radiation therapy combo compared with 9.9 months for patients treated with radiation alone.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.